The World: Washington - Bayer Healthcare forced by FDA to pull Yaz ad

Concerns were expressed by the US Food and Drug Administration that the 60-second ad had gone too far in suggesting that the drug could help overcome PMS and acne.

The ad, by Young & Rubicam, was created to promote the fact that Yaz is approved as a treatment for premenstrual dysphoric disorder (PMDD).

However, the FDA said that the ad significantly failed to distinguish between PMDD and PMS, a problem that the drug isn't approved to treat.